Our findings reveal GCNT1 can alter the glycome of prostate cancer cells, specifically by upregulating the expression of core 2 O-glycan structures (including the cancer-associated glycan SLeX) and modifying the O-glycosylation of secreted glycoproteins. Here, GCNT1 is linked to prostate cancer.